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Introduction 
Vasoactive substances from carcinoid tumors, which are un-
common malignancies arising from enterochromaffin cells, un-
derlie the systemic manifestations of carcinoid syndrome. Pri-
mary ovarian carcinoid tumors are rare, accounting for 0.5% of 
all carcinoid tumors,1) and carcinoid syndrome and carcinoid 
heart disease are believed to complicate fewer than 10% of 
these rare ovarian neoplasms.2) Such tumors are usually suspect-
ed on detection of a pelvic mass and the presence of carcinoid 
syndrome, which is characterized by facial flushing and diar-
rhea, or typical carcinoid heart disease (right-sided valvular in-
volvement).3) Most carcinoid tumors have to metastasize to the 
liver to result in symptoms of carcinoid syndrome; however, 
primary ovarian carcinoid tumors are unique in this regard be-
cause the venous drainage of the ovaries bypasses the portal ve-
nous system.4) We report the case of carcinoid heart disease as-
sociated with a surgical biopsy-confirmed primary ovarian 
carcinoid tumor.
Case
A 60-year-old woman was admitted to our hospital with a 
three-month history of pitting edema of both lower extremi-
ties, worsening dyspnea on exertion, and easy fatigability. She 
had no specific cardiovascular risk factors except for hyperten-
sion. On physical examination, heart sounds were regular, and 
a grade III-IV pansystolic murmur was heard along the left 
lower parasternal border. In addition to pitting edema of the 
lower legs, facial flushing with telangiectatic skin changes was 
apparent in her face and legs. Routine laboratory examination 
including complete blood cell counts and liver or renal func-
tion tests did not reveal any abnormalities. Cardiomegaly was 
apparent on chest X-ray, and transthoracic echocardiography 
showed a normal left ventricular (LV) ejection fraction (56%), 
normal LV systolic and diastolic dimensions, and trivial mitral 
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Carcinoid heart disease is characterized by heart valve dysfunction as well as carcinoid symptomatology. We report a case of 
carcinoid heart disease associated with a primary ovarian tumor. A 60-year-old woman presented for dyspnea evaluation with a 
history of facial flushing, telangiectatic skin changes, and pitting edema of both lower extremities. Chest radiography showed 
cardiomegaly, and echocardiography revealed an isolated, severe tricuspid regurgitation without left-sided valvular dysfunction. 
The tricuspid leaflets were severely retracted and shortened, resulting in poor coaptation. Furthermore, mild pulmonary valve 
stenosis and moderate regurgitation were found along with this deformation. The 24-hour urine analysis revealed an increased level 
of 5-hydroxyindoleacetic acid, and an ovarian tumor was apparent on computed tomography images. The mass was surgically 
removed, and the patient was diagnosed as having a primary ovarian carcinoid tumor. She was treated with chemotherapy and 
regularly followed-up with supportive treatments, deferring surgical correction. 
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regurgitation. However, on right-sided heart evaluation, the 
tricuspid valve (TV) leaflet was severely retracted and short-
ened, and its chordae were also small and deformed (Fig. 1A 
and B). The TV leaflets showed very restricted movement and 
poor coaptation during the systolic phase. Accordingly, severe 
tricuspid regurgitation (TR) was noted on color Doppler im-
aging, and the TR velocity was measured at 2.7 m/s (Fig. 1C 
and D). Deformation was also apparent in the pulmonary 
valve (PV); the PV leaflets shrunk in size and had a motion 
limitation (Fig. 2A). Thus, moderate regurgitation was noted 
on color Doppler images (peak velocity, 1.5 m/s) (Fig. 2B and 
C). Together with regurgitation, color flow was accelerated 
through mild stenosed PV (peak velocity, 1.8 m/s) because of 
retracted PV annulus and stiffened leaflets (Fig. 2D, E and F). 
In addition to this valvular dysfunction, the right ventricle was 
enlarged, and apical contraction was depressed on echocar-
diography. 
We sought systemic or hormonal etiologies for the exclu-
sively right-sided valve involvement in this patient. The 24-
hour urinary level of 5-hydroxyindoleacetic acid (5-HIAA) 
was measured, and abdominal computed tomography (CT) 
imaging was performed. On CT images, an intra-abdominal 
mass was detected on the right ovary (Fig. 3A), and we con-
firmed the increased level of 5-HIAA (68.2 mg/24 hr, normal 
range; 2.0-8.0 mg/24 hr) in 24-hour urine collection. The mass 
was surgically removed; it was 80 × 124 × 78 mm in size with 
an irregular multinodular shape and solid in nature (Fig. 3B). 
Histologically, the sections from the ovarian tumor displayed 
uniform, polygonal cells arranged in solid sheets with a tra-
becular pattern (Fig. 4A, 100×, hematoxylin-eosin staining). 
The trabeculae were lined with one to two layers of cells. The 
cells showed central, monotonous, and round nuclei with no 
mitoses or atypia (Fig. 4B, 400×). The amount of cytoplasm of 
the constituent cells was large, and it was strong acidophilic. 
Immunohistochemical analysis of the tumor cells showed 
strong granular cytoplasmic positivity for chromogranin A 
(Fig. 4C, 100×, chromogranin staining). Finally, the patient 
was diagnosed as having a primary ovarian carcinoid tumor. 
She was treated with adjuvant chemotherapy including pacli-
taxel and carboplatin and was subsequently discharged with-
out any worsening complication. Treatment with diuretics and 
angiotensin converting enzyme inhibitors was continued to re-
lieve right heart failure (HF) symptoms, with slight improve-
ment of pitting edema and dyspnea. Follow-up echocardiog-
Fig. 1. Echocardiographic imagings showing a deformed tricuspid valve with regurgitation. The echocardiogram on apical four-chamber view shows 
an enlarged right atrium and right ventricle. Both anterior and septal leaflets (arrows) reveal thickened and retracted (A). On the right ventricular inflow 
view, both anterior and posterior leaflets also show no mobility, shortening, and coaptation failure (B). Severe tricuspid regurgitation is noted on color 
Doppler imaging (C). Continuous-wave Doppler signal of tricuspid regurgitation shows an early peak velocity and a rapid decline, shaping dagger-
shaped “V” wave (velocity, 2.7 m/s) (D). RV: right ventricle, RA: right atrium, LA: left atrium, TV: tricuspid valve, TR: tricuspid regurgitation. 
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raphy 3 months later showed no improvement of the valve 
deformity or TR severity; surgical correction, i.e., the replace-
ment of the deformed valve using mechanical or bioprosthet-
ics, was therefore considered to reduce right HF symptoms 
and to substantially delay the deterioration of right ventricular 
dysfunction. However, the patient wanted to defer surgical 
correction of the severe TR and to remain on conservative 
medical therapy because of the stated satisfaction with the 
Fig. 2. Echocardiographic imagings showing a deformed pulmonary valve with regurgitation and stenosis. Parasternal short axis view of the 
pulmonary valve which has thickened and shortened leaflets (arrows); in addition, pulmonary annular contraction is present in zoomed imaging (A 
and D). On color Doppler imaging, moderate pulmonary regurgitation is shown and its peak velocity is at 1.5 m/s (B and C). Simultaneously, color 
flow is accelerated in systolic phase due to the stiffened and constricted leaflets (peak velocity, 1.8 m/s) (E and F). RV: right ventricle, Ao: aorta, PV: 
pulmonary valve, PR: pulmonary regurgitation, PS: pulmonary stenosis.
COLOR 
Fig. 3. Computed tomographic findings of carcinoid tumor. A large mass with inhomogenous density occupies the right pelvic cavity. The mass 
(white arrow) consists of multiple thick-enhancing septa and enhancing central soft tissue density (A). The right ovary is grossly enlarged; it is 
measured to be 80 × 124 × 78 mm in size and to weigh 461 g. The ovarian surface is smooth. The cut surface of the mass is bright yellow and solid, 
and it shows several foci of hemorrhage (B).
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clinical response and tolerability. Three years after diagnosis, 
she remains clinically stable; she has mild dyspnea on exertion 
in daily activities, and she is regularly followed-up at the out-
patient clinic. 
Discussion
Carcinoid heart disease can manifest in more than half of 
patients with carcinoid syndrome. However, primary ovarian 
carcinoid tumors, accounting for 0.5% of all carcinoid tumors, 
are very rare, and fewer than 10% of primary ovarian carcinoid 
tumors are associated with carcinoid syndrome.1)2)
Patients with carcinoid heart disease exhibit fibrotic valvu-
lar plaques and myofibroblast proliferation that may cause val-
vular thickening and retraction leading to dysfunction.5) Most 
patients present with right-sided heart valve dysfunction be-
cause of the venous drainage of a vasoactive substance that is 
metabolized and secreted by the liver; left-sided valve dysfunc-
tion, which is usually accompanied by coronary vasospasm, is 
present as the result of a patent foramen ovale in less than 10% 
of individuals with carcinoid heart disease.6-8)
Despite an unusual manifestation of myocardial infiltrative 
pattern,9) echocardiography of patients with carcinoid heart 
disease has characteristic findings of thickened, shortened, and 
retracted TV and PV leaflets, changes that lead to incomplete 
coaptation, resulting in moderate or severe TV/PV regurgita-
tion. Moreover, the PV is thickened and retracted, which also 
causes pulmonary regurgitation. Most findings can be explained 
by the systemic effects of 5-HIAA, which is activated via he-
patic metabolism and drains into the right-sided heart sys-
tem.8)10)11) Thus, importantly, severe TR alone without mitral 
valve involvement should raise suspicion of carcinoid heart 
syndrome as the cause of right-sided valvular heart disease. 
There is no consensus on the appropriate treatment of carci-
noid heart syndrome to improve mortality. In general, early 
detection and surgical removal of primary carcinoid tumors 
seems to be the only effective treatment that results in favor-
able clinical outcomes; two-year survival with surgical remov-
al has been reported to be 40%, whereas that of medical treat-
ment without surgery is only 8%.12) Because of systemic or 
hormonal effects, surgical removal would not be sufficient to 
treat carcinoid heart disease or to promote the regression of 
valvular lesions. With the recent decrease in valvular perioper-
ative mortality, surgical correction of TV dysfunction could be 
generally undertaken, even in mildly symptomatic patients, 
to prevent further HF progression, right HF symptoms or 
signs, such as right ventricular enlargement or decline in right 
ventricular systolic function, or in anticipation of hepatic sur-
gery.13) In the case of carcinoid syndrome with echocardio-
graphic evidence of cardiac involvement, the three-year sur-
vival is reported to be 31%.14) Thus, individualized surgical 
correction of TV and right HF treatments are also needed to 
achieve better outcomes.
In conclusion, this case suggests that, in the differential di-
agnosis, we should consider a rare condition such as carcinoid 
heart disease; this condition is characterized by isolated, severe 
TR without significant left-sided valvular dysfunction, which 
could be easily assessed by transthoracic echocardiography.
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